M&A
confidence high
sentiment positive
materiality 0.90
Onconetix agrees to reverse merger with Ocuvex; Ocuvex holders to own 90% of combined company
Onconetix, Inc.
- Onconetix acquires Ocuvex; Ocuvex holders get 90% of combined co, Onconetix holders 10%.
- Post-close board: 7 directors (5 Ocuvex, 2 Onconetix); closing targeted Q4 2025.
- Series C Preferred conversion price reduced to $3.50 effective through July 31, 2025.
- Andrew Oakley elected Lead Independent Director, to receive $36,000/month.
- Nasdaq compliance regained; subject to Mandatory Panel Monitor through July 2026.